Autopsy report · NCT05149807

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

“R\&d strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 81 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Sponsor type

Industry

Conditions

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Interventions

SHR-1701 injection; Placebo

Participants

81

Sites

20

Countries

China

Trials that died the same way

• A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
  “changes in the R\&D strategy” (86% match in meaning)
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
  “Sponsor R \& D Strategy Adjustment” (76% match in meaning)
• Choroidal Changes Post Short Term Exposure To Virtual Reality Devices
  “Strategy change” (69% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (69% match in meaning)
• A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  “Sponsor's R\&D strategy adjusted.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.